Cambrex has expanded its stability storage business, Q1 Scientific, in Ireland and Belgium.
Cambrex announced on Oct. 4, 2022 the expansion of Q1 Scientific, its stability storage business, which offers environmentally controlled stability storage services to the pharmaceutical, medical device, and life sciences industries. Its existing facility in Waterford, Ireland will have an additional 10,000 ft2 expansion, and a new 20,000 ft2 current good manufacturing practices (CGMP) facility will be opened in Belgium.
The new temperature-controlled and monitored storage facility in Belgium will be located in the Liege region. The facility will provide 35,000 temperature-controlled storage spaces. The Waterford-based Ireland facility has doubled in size over the past two years and continues to grow with this new 10,000 ft2 expansion.
“With Cambrex’s scientific expertise and scale, we are able to accelerate our growth plans and launch a second site in 2023,” said Stephen Delaney, managing director of Q1 Scientific, in a company press release. “Operating two sites will be a great benefit to our European customers, who can now expect even faster turnaround times for the return of samples. Meanwhile, we will also be able to provide greater temperature-controlled transport options in mainland Europe.”
Source: Cambrex
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Entering New Domains for 3D Printing of Drug Products
April 6th 20253D printing of personalized medications is currently possible under existing compounding regulations, offering enhanced process control through automation. But new legislation coming in 2025 will allow 3D printing as part of a distributed manufacturing framework.